ReviewClinical kidney journal2023
SGLT-2 inhibitors in nephrotic-range proteinuria: emerging clinical evidence.
Review in Clinical kidney journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed.
- Clinical value of adding Dapagliflozin in patients with nephrotic syndrome.International urology and nephrology · 2024Trial
- Tacrolimus to belatacept conversion in proteinuric kidney transplant recipients.Frontiers in immunology · 2024Trial
- Beyond the Amount: The Selectivity of Proteinuria and Risk of Graft Failure in Kidney Transplant Recipients.American journal of nephrology · 2026Article
- Comparison of SGLT2 Inhibitors for New-Onset Proteinuria Risk in Patients With Type 2 Diabetes and Preserved Kidney Function.Diabetes, obesity & metabolism · 2026Article
- Real-World Experience With Dapagliflozin in Non-diabetic Chronic Kidney Disease: A Case Series From India.Cureus · 2026Article
- Dynamics and Predictive Values of Urinary Podocyte Biomarkers Following SGLT2 Inhibition in CKD.Life (Basel, Switzerland) · 2026Article
- The Role of Complement Component C5a in the Pathogenesis of Diabetic Kidney Disease: A New Kid on the Block?Cureus · 2026Review
- Triple therapy of RAS inhibitors, dapagliflozin, and finerenone in diabetic kidney disease patients with nephrotic-range proteinuria: a real-world study.Scientific reports · 2025Article
- Prognostic impact of proteinuria in diabetic patients without chronic kidney disease undergoing percutaneous coronary intervention.Cardiovascular diabetology. Endocrinology reports · 2025Article
- Association of fructose-1,6-diphosphatase 1 with the progression of diabetic kidney disease.Nutrition & metabolism · 2025Article
- Expanding the Therapeutic Landscape: Sodium-Glucose Co-transporter 2 Inhibitors in Kidney Transplant Recipients.Cureus · 2025Review
- Alternative pathway-mediated tubular complement activation in human proteinuric kidney diseases: a proof-of-concept study.Clinical kidney journal · 2025Article
- Peripartum dapagliflozin improves late-life maternal cardiovascular outcomes in a murine model of superimposed preeclampsia.American journal of obstetrics and gynecology · 2025Article
- Systolic blood pressure is associated with early and long-term changes in renal function in patients with dapagliflozin-treated moderate-to-advanced chronic kidney disease.Clinical and experimental nephrology · 2025Article
- Risk of age-related macular degeneration according to the chronic kidney disease and proteinuria in Korea: a 10-year nationwide cohort study.Scientific reports · 2025Article
- Advanced chronic kidney disease coexisting with heart failure: navigating patients' management.Clinical kidney journal · 2025Review
- SGLT2 Inhibitors: The First Endothelial-Protector for Diabetic Nephropathy.Journal of clinical medicine · 2025Review
- Membranous Nephropathy.Journal of clinical medicine · 2025Review
- The effects ofRenal failure · 2024Article
- Drug repurposing for glomerular diseases: an underutilized resource.Nature reviews. Nephrology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose cotransporter-2 (SGLT-2) inhibitors are a class of novel oral anti-hyperglycemic agents which are increasingly used in clinical practice. SGLT-2 inhibitors improve glycemic control and cardiorenal outcomes, promote weight loss, and reduce blood pressure. Randomized controlled trials have demonstrated that SGLT-2 inhibitors reduce proteinuria and delay progression of kidney disease in patients with albuminuria. However, whether SGLT-2 inhibitors have similar benefits in patients with nephrotic-range proteinuria has not been well established. Evidence to date has been limited to case reports, case series and secondary analyses of randomized controlled trials. This is the first comprehensive review on the effectiveness of SGLT-2 inhibitors for the treatment of patients with nephrotic-range albuminuria or proteinuria. Overall findings support a likely beneficial role of SGLT-2 inhibitors in reducing proteinuria and delaying chronic kidney disease progression in patients with nephrotic-range proteinuria.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.